Serveur d'exploration Tocilizumab

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Région de Kantō222
Y. Kaneko5
Région de Kantō Sauf Y. Kaneko" 217
Y. Kaneko Sauf Région de Kantō" 0
Région de Kantō Et Y. Kaneko 5
Région de Kantō Ou Y. Kaneko 222
Corpus6869
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 5.
Ident.Authors (with country if any)Title
002D30 T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. MimoriOP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study)
003071 Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon]AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study
003111 K. Izumi [Japon] ; Y. Kaneko [Japon] ; H. Yasuoka [Japon] ; N. Seta [Japon] ; H. Kameda [Japon] ; M. Kuwana [Japon] ; T. Takeuchi [Japon]AB0544 Efficacy and safety of tocilizumab in patients with rheumatoid arthritis in the presence or absence of previous treatment with biologics and concomitant treatment with methotrexate
003177 Y. Kaneko [Japon] ; M. Kuwana [Japon] ; H. Kameda [Japon] ; T. Takeuchi [Japon]AB0347 Validation of the clinical remission criteria in rheumatoid arthritis at keio immunotherapy center
003199 K. Izumi [Japon] ; Y. Kaneko [Japon] ; H. Yasuoka [Japon] ; N. Seta [Japon] ; H. Kameda [Japon] ; M. Kuwana [Japon] ; T. Takeuchi [Japon]AB0319 Treatment with tocilizumab improved rheumatoid arthritis patients clinically and structurally regardless of the prior use of anti-tnf biologics in daily clinical practice

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021